Latest Headlines

  1. 3PBIOVIAN Strengthens Its End-To-End CDMO Offering With State-Of-The-Art Sterility Testing, From Clinical To Commercial 5/7/2026

    3PBIOVIAN has significantly strengthened its sterility testing capabilities, reinforcing its position as an integrated, end-to-end CDMO serving biopharma customers from early development through commercial supply.

  2. Made Scientific And RoosterBio Announce Strategic Technology And Supply Partnership To Expand Scalable MSC And Extracellular Vesicle Manufacturing 5/5/2026

    Partnership integrates RoosterBio's mesenchymal stem cell and extracellular vesicle platforms into Made Scientific's end-to-end CDMO capabilities to accelerate development and commercial-scale production of advanced therapies.

  3. AES Cleanroom Technology appoints John Groth As Chief Revenue Officer 4/27/2026

    AES Cleanroom Technology, a leading provider of modular cleanroom design, manufacturing, and construction solutions for the life sciences and biopharmaceutical industries, has appointed John Groth as Chief Revenue Officer as demand grows for flexible, high-performance manufacturing environments across pharma and biotech.

  4. Contec, Inc.® Partners With i-team Global To Deliver Cleanroom-Certified, Battery-Powered Mechanized Cleaning System 4/24/2026
  5. Minaris Delivers 100% Manufacturing And Release Success For Chimeric Therapeutics' CDH17 Autologous CAR‑T Program 4/23/2026

    Minaris, a global cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) and multimodality biosafety testing provider and Chimeric Therapeutics (ASX: CHM, “Chimeric” or the “Company”), a leading Australian cell therapy company, today announced a 100% batch manufacturing and release success rate in support of Chimeric Therapeutics’ CDH17-targeted autologous CAR-T program in Phase 1A/1B for gastrointestinal (GI) cancers, including colorectal and gastric cancer as well as neuroendocrine cancers.

  6. One Brand Uniting Critical Fluid Management Components 4/17/2026

    CPC Biotech to make its public debut at INTERPHEX 2026, April 21–23, Javits Center, New York City.

  7. CDMO Kincell Bio Announces Expansion Of North Carolina Manufacturing Hub 4/15/2026

    Kincell Bio, a leading contract development and manufacturing organization (CDMO) supporting autologous and allogeneic cell therapy programs, today announced a significant strategic investment to expand and strengthen its Research Triangle Park (RTP), North Carolina, facility. The expansion reinforces Kincell Bio’s commitment to supporting clients as they advance from late-stage clinical CMC development through commercialization and post-approval life cycle management.

  8. AST And Marchesini Group Debut Partnership Benefit With Expanded Drug Product Manufacturing Portfolio At INTERPHEX 2026 4/14/2026
  9. Ensorcell Launches Versaweld™ Precision Tube Welding Platform At INTERPHEX 2026 4/10/2026
  10. Bracco Investing In Geneva Facility To Scale Cell Therapy Manufacturing 4/2/2026

    Bracco Imaging, a global pharmaceutical company that develops, manufactures, and markets innovative healthcare solutions, announced an upgrade of its manufacturing site in Geneva to support clinical-grade GMP manufacturing of its cell therapy-enabling microbubble technology, building on its previously announced investments in the site since 2019. Commercial access to the GMP-grade cell selection and activation product will be ready by the middle of 2027.